The Arcanum: A Supernatural Espionage Urban Fantasy Series
- 306bladzijden
- 11 uur lezen
Jon staat bekend om zijn bovennatuurlijke actieromans, met name de Lawson Vampire-serie, met een verbitterde antiheld die belast is met het beschermen van een ras levende vampiers tegen ontdekking. Zijn uitgebreide bibliografie omvat meer dan 40 romans, waaronder een internationaal succesvolle avonturenserie, die een dynamische schrijfstijl laat zien. Zijn werk duikt vaak in thema's van morele ambiguïteit en overleven, geïnformeerd door zijn diepe achtergrond in vechtsporten en beschermingsdiensten. Lezers kunnen spannende verhalen verwachten die duistere fantasy combineren met actie met hoge inzetten.






(#6 in the Bestselling Lawson Vampire Series)En route to Japan, Lawson gets an emergency message asking him to touch down in the Philippines where a series of events have unfolded that jeopardize the secrecy of the existence of the vampire race. Alone, with no friends to call upon, Lawson must unravel the conspiracy afoot and take steps to prevent classified information from falling into the wrong hands. But even as he starts to figure out who the culprits are, new enemies emerge - and each one more deadly than the last.PAPERBACK includes THE PRICE OF A GOOD DRINK (Lawson Vampire #5) About the Author: Jon F. Merz is the author of over 30 novels (including the bestselling Lawson Vampire supernatural espionage series) ranging from urban fantasy to espionage and sword & sorcery fantasy. Prior to becoming a full-time writer Jon served in the United States Air Force, protected a variety of Fortune 500 executives, and taught defensive tactics to government agencies like the State Department, Bureau of Prisons, and others. He is an active CrossFitter, a 5th degree black belt in Togakure-ryu Ninjutsu, enjoys doing GORUCK challenges, and in 2014 started modeling and acting, most recently starring as Alfred P. Sloan in THE CARS THAT MADE AMERICA on the History Channel. He lives each and every day by the motto, "Who Dares Lives."
In this installment of the Lawson Vampire series, the protagonist is a cynical vampire tasked with maintaining the secret of a hidden race of living vampires. Blending espionage and combat skills, he faces off against Shiva, a lethal half-vampire assassin with the ability to shapeshift, who targets the head of the vampire governing body. The plot thickens with the pursuit of the Lunaspe, an ancient amulet that promises invulnerability. This action-packed narrative combines supernatural elements with a noir atmosphere, showcasing Merz's signature fast-paced storytelling.
The story features Lawson, a unique vampire who diverges from traditional bloodsucking norms. Instead of craving blood, he navigates a world filled with intrigue, akin to a supernatural spy thriller. This character offers a fresh take on vampire lore, blending action and suspense with a twist on the vampire mythos. Readers can expect an engaging narrative that explores themes of identity and morality in a world where not all vampires conform to expected behaviors.
This special issue of 'Community Genetics' addresses human gene patenting. Patenting human genes has been controversial since day one, with proponents asserting that patents are necessary to promote investment in the development of therapies and cures, and with opponents arguing that gene patents are immoral and unethical. This publication contains papers written by scientists, lawyers, social scientists and policy analysts, representing a broad-range perspective on the benefits and burdens of gene patenting. While some data have accumulated as the corpus of gene patents has expanded, the papers show that the underlying questions about consequences, both pro and con, remain unanswered. These issues first came to a head more than a dozen years ago when the US National Institutes of Health filed patent applications on thousands of gene fragments called Expressed Sequence Tags, and they have spread to other developed countries. Providing a balanced, international overview of gene patenting practices and experiences, this publication will be of interest to scientists, lawyers, policy analysts and others who are interested in biotechnology, intellectual property, innovation and genetic medicine.